![Does Offering Free Access to Drug Pricing Tool Cross the Kickback Line?](https://www.g2intelligence.com/wp-content/uploads/2022/06/June2-2022.News_.KickbackCase-iStock-1800x1250-1-1080x675.jpg)
Does Offering Free Access to Drug Pricing Tool Cross the Kickback Line?
NY federal court ruling sheds light on what constitutes “remuneration” banned by the Anti-Kickback Statute.
NY federal court ruling sheds light on what constitutes “remuneration” banned by the Anti-Kickback Statute.
New OIG Advisory Opinion offers valuable insight into where the agency draws the line on free genetic tests.
Of this month’s four Labs in Court cases, three involved kickbacks resulting in widely varying penalties.
Settlements for False Claims Act allegations the theme in recent enforcement actions involving the healthcare industry.
On April 11, the OIG approved a proposed arrangement involving the offering of free genetic tests and counseling services.